| A direct C11 alkylation strategy on the saxitoxin core: a synthesis of (+)-11-saxitoxinethanoic acid SR Paladugu, CK James, RE Looper Organic letters 21 (19), 7999-8002, 2019 | 15 | 2019 |
| Preparation of a 1, 2-isoxazolidine synthon for the synthesis of zetekitoxin AB SR Paladugu, RE Looper Tetrahedron letters 56 (46), 6332-6334, 2015 | 12 | 2015 |
| Tris(4-bromophenyl)aminium Hexachloroantimonate-Mediated Intermolecular C(sp2)–C(sp3) Free Radical Coupling of Vindoline with β-Ketoesters and Related … J Zhang, SR Paladugu, RM Gillard, A Sarkar, DL Boger Journal of the American Chemical Society 144 (1), 495-502, 2021 | 7 | 2021 |
| Compounds as inhibitors of axl JW Beatty, CN Foley, GAL Balint, M Lamani, MR Leleti, DH Miles, ... US Patent App. 18/341,844, 2023 | | 2023 |
| AB801 is a highly potent and selective AXL kinase inhibitor that demonstrates significant anti-tumor activity SL Paprcka, A Goshayeshi, S Liu, R Flores, L Rocha, JL Leslie, DH Miles, ... Cancer Research 83 (7_Supplement), 518-518, 2023 | | 2023 |
| Axl compounds CN Foley, M Lamani, MR Leleti, DH Miles, P Nareddy, S Paladugu, ... WO Patent WO2,022,246,177, 2022 | | 2022 |
| Axl inhibitor compounds CN Foley, M Lamani, MR Leleti, DH Miles, S Paladugu, JP Powers, S Qu, ... WO Patent WO2,022,246,179, 2022 | | 2022 |
| Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801 D Miles, S Paprcka, C Foley, S Qu, M Lamani, S Paladugu, HT Huang, ... European Journal of Cancer 174, S103, 2022 | | 2022 |
| Potent and selective AXL tyrosine kinase inhibition demonstrates significant anti-tumor efficacy in combination with standard of care therapeutics in preclinical models SL Paprcka, S Sridhar, I Luu, S Jafri, D Miles, S Liu, R Flores, S Qu, ... MOLECULAR CANCER THERAPEUTICS 20 (12), 2021 | | 2021 |
| Synthetic Studies on C11 Alkylated Bis-Guanidinium Sodium Ion Channel Inhibitors 11-Saxitoxinethanoic Acid and Zetekitoxin AB SR Paladugu The University of Utah, 2019 | | 2019 |
